Skip to content
  • Education Center
  • Vital
  • Shop
  • Navigators
Site Logo
  • Podcasts
  • Articles
  • Events
  • About

Subscribe to Our Podcast

Post Tag: Research

Posted on September 22, 2023September 26, 2023

PT444 – A Glimpse Into the Psychedelic Neuroscience Landscape

In this special episode, Melanie Pincus, Ph.D. and Manesh Girn, Ph.D., who joined David in episode 403 to discuss the launch of their new course, essentially interview each other.

As the 2nd edition of their popular course, Psychedelic Neuroscience Demystified, begins on November 1, we wanted to give them a chance to highlight some of the aspects of neuroscience students can expect to learn in the course, and what so many people who are interested in psychedelics don’t fully understand: What does neuroplasticity actually entail? Can one predict if a patient is more apt to have an experience with ego dissolution? How does the amygdala relate to mood disorders? When are critical periods of greater plasticity and socialization at their most beneficial? How does neuroplasticity relate to chronic stress?

They also discuss lessons they’ve received from their own journeys; why they created the course; serotonin; psychological flexibility; body-based versions of self vs. memory-based versions; psychedelics and re-encoding memories (and the potential for false memories); how psychedelic therapy is different from standard drug treatments; psychedelics and the default mode network (is the story oversimplified?), and much more. 

For more information on their course, and to sign up, click here!

Notable Quotes

“A major insight from my psychedelic journeys is just how dense and heavy thoughts and mental content can be. And we often feel the need to overanalyze and think about things and get lost in our concepts and internal dialogue as opposed to experiencing things in the moment, as they are, in a more deeper kind of intimate way – having a greater intimate relationship with our senses, with the immediacy of what’s happening. And my psychedelic experiences, whether it’s with psilocybin or 5-MeO-DMT or what have you, have allowed me to glimpse into states where that stuff is just totally removed, and I’m just immersed in the rawness of experience and just how beautifully vibrant and alive and spontaneously intelligent that is, and how superfluous a lot of our thinking really is, and it just weighs us down. I think my journeys have just allowed me to live with greater ease and hold on to my identity and my narratives much more lightly. So I see them, I acknowledge them, but I’m not totally lost in them. I don’t identify strongly with them.” -Manesh

“Perhaps what’s happening is that MDMA induces a super positive mood where you feel really socially connected, really empathogenic with your therapist or whoever’s around you, you feel so safe and supported. And so if challenging traumatic memories come up, there’s this mismatch between the emotional trace of the traumatic memory and the unique state you’re in with the MDMA on board. And so this mismatch drives the memory reconsolidation process so that your traumatic memory is amended with less fear to be more in line with your current way you’re feeling of being so safe and supported.” -Melanie

Links

Psychedelic Neuroscience Demystified: How Psychedelics Alter Consciousness and Produce Therapeutic Effects

Opening Critical Periods with Psychedelics, by Melanie Pincus, Ph.D. & Manesh Girn, Ph.D.(c)

Frontiersin.org: Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique

PT403 – Understanding the Brain: Psychedelic Neuroscience Demystified, featuring: Melanie Pincus, Ph.D. & Manesh Girn

PT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and Creativity

The Psychedelic Scientist YouTube

Posted on September 8, 2023September 8, 2023

PT440 – Coming Back to Stillness, Microdosing and Adaptogens, and What We Can Learn From Autism

In this episode, David interviews Dr. JoQueta Handy, Ph.D., IMD: speaker, author, educator, Natural Integrative Health Practitioner, and CEO and Chief Visionary of Brilliant Learning, Handy Wellness Center, and Brilliant Blends.

She shares childhood memories of growing up on her Grandparents’ farm, where she developed a deep appreciation for nature, staring at the stars, and the beauty in stillness, and how coming back to that stillness has been key in her life and psychedelic journeys. The conversation then shifts to all that she’s learned through her work with children on the autism spectrum: the problems of putting people into boxes; how autism affects everyone; the different ways people learn; the connection between autism and the gut microbiome; and how she has learned more from some of these children than any book could teach her – culminating in a story of discovering that a very challenged child people were ready to give up on could actually read and comprehend everything he was hearing.

She discusses her favorite adaptogens; the art of stacking adaptogens and different modalities; her multi-day coaching sessions; Internal Family Systems; quantum biofeedback; the use of supplements in microdosing; and Brilliant Blends, which sells blends of supplements designed to provide benefits as close to what psilocybin can provide (but legally) – inspired by the unique needs of autistic individuals. PT listeners can receive 10% off all purchases with code: PT10.

Notable Quotes

“If we look at Western medicine, we are masters at saving lives. We’re not so great at quality of life. And looking more toward Eastern medicine, European medicine: where body, mind and soul [is] more brought into play – healing, working on the mind, the emotional, the mind and the body for a complete healing… So that was really why I chose the path of natural integrative medicine because I did see that everything has a place. Everybody brings a talent to the table. …We, many times, need a village for healing.”

“I’ve had some wonderful mentors along the way, but being on the ground, so to speak – not just in a laboratory, formulating things – being hands-on with those children on a day-to-day basis: that was the greatest teacher of: how is this herb working? How is this adaptogen working? So when I went to formulate Brilliant Blends, I just knew it had to honor them because I was using that knowledge base. I use it on a daily basis with everyone. …Autistic children have taught us what we know from autism, and what we know from autism applies to everyone.”

“That’s the end game. That’s the bottom line in all of this work that we’re doing. That’s where the transformation and freedom is: to realize that this medicine is in all of us. Maybe we’re just using psychedelics to open that door to reveal it and show us the path how to anchor it, but this medicine is in all of us and always was. So if we can use these different pathways, these different approaches to lead us back home, then bravo.”

Links

Drjoquetahandy.com

Mybrilliantblends.com (use code PT10 to receive 10% off all purchases)

Drhandy.com

3cosevents.com

Brilliantlearningonline.com

Hemplucid.com (use code PSYCHEDELICS10 for 10% off all purchases)

Posted on August 11, 2023August 11, 2023

PT431 – The Concept of Integration and the Need for Evolving Protocols of Psychedelic Therapy

In this episode, Kyle interviews The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins, and renowned researcher of nearly 20 years: Matthew W. Johnson, Ph.D.

Recorded in-person at MAPS’ Psychedelic Science after running an 8-hour workshop on psychedelic therapy for addiction treatment, Johnson was still happy to sit down with PT to explore a wide range of topics: the under-researched concept of integration; how to best take advantage of optimal neuroplastic windows; why psycholytic therapy used to be more common; how our current protocols and research models are largely arbitrary; and his hopes for new, experimental, and flexible models of psychedelic therapy.

He also discusses his ongoing smoking cessation studies; the Oregon model (are we doing therapy or not?); misrepresentation in psychedelic therapy and knowing your lane; and the role of music in psychedelics: why shouldn’t people pick the music they know will give them goosebumps?

Notable Quotes

“How in the world could there be these beneficial effects that we can see in someone’s behavior (their substance use, their depression) 6 months, a year later from one, two, or three medication experiences that were time-limited? …People are changing the way they’re operating. And the more you start to do that, and that starts to become the new normal, so it’s not just ending at the psychedelic session or even in the explicit integration sessions where you talk about your psychedelic therapy or your psychedelic session; but then, if you put into practice – like actually changing the way you’re operating in the world and that becomes the new normal – I think that’s what’s happening to explain why we’re seeing these beneficial effects six months, a year later. It’s just kind of the causal nature of the therapeutic mechanisms unfolding over time in a kind of a living, organic way, because people are interfacing with reality in a different way, that can, if they’re doing it right, it can have a feed-forward effect, like, ‘Oh, this actually works. I feel better. I’m doing better in life when I do things more this way than the way I used to do them.’”

“The nice thing that’s probably going to happen once we get out of this phase, at least with, like, psilocybin and MDMA where it’s only in clinical approved research now, if they’re approved by the FDA for straight up treatment, FDA is not going to control what music you use or how you integrate and all these other things. And so there’s going to be this wave of naturalistic experimentation which is going to be really cool. And then hopefully people are safe, but hopefully there’s an integration of the communication of the art of the practice of medicine and psychology. It’s like just through that communication – like what tends to work, what tends not to work, people sharing ideas – I’m looking forward to that.”

Links

Hopkinsmedicine.org: Matthew W. Johnson, Ph.D.

Psychedelics Today: PT229 – Dr. Matthew Johnson – What is Consciousness?

Join us in the Netherlands for the Kiyumí Psilocybin Retreat & Vital Training: September 6-11, 2023. Click here to learn more and apply!
Posted on August 9, 2023August 9, 2023

Exploring the Vast Potential of Psychedelic Medicine: A Physician’s Perspective on Allopathy, Virtual Community, and Clinical Research

Neurology physician Dr. Burton Tabaac’s interest in psychedelics began almost by accident. He happened upon the topic through a 2019 presentation during his fellowship training at the Johns Hopkins University School of Medicine – and may not have pursued a dedicated interest in the field if he hadn’t attended.

“… In four years of medical school and four years of residency training, psychedelics were not mentioned – not even once as part of a comprehensive allopathic education,” Tabaac told Psychedelics Today.

The Hopkins lecture inspired the physician down a non-typical path for those in his profession: research on the therapeutic potential of psychedelics in treating mental health diseases. Today, he explores psychedelics beyond their traditional association with mental health. Entities inclusive of Parkinson’s disease, dementia, stroke, and traumatic brain injury are of particular intrigue with potential for psychedelics to promote healing, Tabaac shares.

Exploring Psychedelics’ Versatility

In his recently appointed role for the Mckenna Academy of Natural Philosophy, founded by Dennis McKenna, Dr. Tabaac serves as an advisor for educational pursuits and evidence-based methodology. Through this collaboration, he is dedicated to investigating the possible role of psychedelics beyond their use in the mental health realm, and is passionate about exploring whether these substances could help with functional neurological and neurodegenerative diseases.

“There are specific indications that I feel warrant additional study and funding to assess and discover,” he says. “There has already been a lot of research and literature published dedicated to psychedelics for treating depression, anxiety, addiction and PTSD; I’m very eager to partner in pushing the frontier further to investigate what else psychedelics may have the potential to address.”

In the current landscape of psychedelic research, this alliance highlights the evolving role of physicians stepping beyond traditional methods to investigate alternative solutions. The demand for more research signifies a promising future for psychedelic research, with the potential of extending the possibilities of these substances in treating various conditions.

Obstacles to Holistic Approaches

In the healthcare world, it isn’t uncommon to find that many doctors tend to favor Western medicine while overlooking holistic approaches. Doctors don’t typically embrace integrative routes, because the current medical system is guided primarily by evidence-based research, Tabaac says. Treatments typically require strong evidence of their efficacy before they are widely adopted, which doesn’t bode well for most federally scheduled psychedelics in relative nascent stages of research.

“I also think that having psychedelics as a restricted Schedule I class of drugs prohibits a lot of providers from even being able to offer these therapeutics off-label,” he says. “When you look at where the medical/legal field is heading, there’s a lot of promise with the Phase 3 trial that MAPS has presented demonstrating the potential for MDMA to treat PTSD.”

PTSD patients in the MAPS study received three doses of MDMA, supplemented with psychotherapy. The trial results yielded 50 per cent of participants no longer meeting the criteria for PTSD. One year later, without any additional MDMA doses, the number of patients no longer meeting the criteria increased to 70 per cent, “showing that there is some underlying effect on the brain that is sustainable,” Tabaac said.

The MAPS study highlights the transformative impact that psychedelics – combined with psychotherapy – can have on mental health disorders like PTSD, Tabaac says. As more research emerges, it is expected that the medical community will gradually embrace these alternative treatments and integrate them into mainstream healthcare, ultimately empowering physicians to treat patients with greater efficacy and enriching the field of allopathic medicine.

The Power of Virtual Community for Doctors

Back in December 2021, Tabaac stumbled across the Psychedelics Anonymous (PA) platform, a web3 community that shared his enthusiasm for the potential of NFTs to bridge communities of like minded individuals. PA offers a secure environment where members can connect without revealing their identities, utilizing avatars to engage in discussions about psychedelics, and exchange personal or professional experiences. 

Membership in Psychedelics Anonymous brought with it additional perks, Tabaac said, offering access to educational opportunities such as a plant medicine course at Cornell and participation in the recent Psychedelic Science 2023 conference in Denver. The project has also established a podcast, The Zero Hour, where Tabaac interviews the top minds in the psychedelic space.  The most valuable aspect, Tabaac says, was the connections made with fellow colleagues. He connected with psychiatrists, psychologists, social workers, and researchers who were curious about psychedelic medicine and established this virtual space where they could openly discuss without stigma, judgment, or fear of retribution.

“I attribute a lot of my own development and personal growth and passion for the space to the Psychedelics Anonymous project, because prior to getting involved in that community, there was trepidation over being judged by friends and by society at large, as a lot of the negative press and stigma still remains, dating back to Nixon’s War on Drugs,” he says. 
Psychedelics Anonymous also catalyzed Tabaac’s passion in the field to present a TEDx talk discussing Mental Health Meets Psychedelics. In this talk listeners are challenged to question their preconceived notions and judgements as it pertains to the group of restricted therapeutics in the psychedelic class. Tabaac asks if this class of drugs can serve as a paradigm shift in the way mindfulness therapy and mental health is approached.

Balancing Passion and Clinical Practice

Dr. Tabaac recognizes the difference between his passion for advancing psychedelic medicine and his commitment to ethics. “I infrequently discuss psychedelics with my patient population, exceptions including clinical trial offerings if inclusion criteria is met. Doctors and health practitioners are constrained by the limits of their medical licensure, and must remain patient until FDA approval is achieved,” Tabaac says. “I think it’s still premature and out of my scope to offer psychedelics to my patients. My mission and my role is better served in pushing clinical  research forward, commiting patient enrollment in trials, and inviting speakers who are experts in the psychedelic space to present on my podcast I incorporate teachings on psychedelics to the medical students that rotate with me as it is the only space where they have exposure to learning about these modalities. The enthusiasm and interest among the next generation of physicians is encouraging.”

The demand for alternative mental health solutions continues to increase. Organizations like the Psychedelic Medicine Association, dedicated to providing ketamine treatments and with whom Tabaac is affiliated, are addressing the needs of individuals seeking non-traditional routes. While certain prescriptions may fall beyond the scope of some physicians, adopting a holistic approach becomes crucial. With physicians like Tabaac considering various facets of a person’s well-being, such as sleep, lifestyle, nutrition, social support, mindfulness practices and physical health, individuals can benefit from more comprehensive and personalized mental health care. This avenue goes beyond medications, recognizing the broader needs of patients. It underscores the importance of tending to various dimensions of a person’s life to foster holistic well-being and empowers individuals to explore diverse modalities for emotional harmony. Tabaac emphasizes the moniker of focusing “mental health as part of whole health.”

The Future of Psychedelic Medicine

For physicians like Tabaac, exploring the uncharted waters of psychedelic medicine opens up new possibilities for patient treatment and professional development. It provides access to innovative therapies, nurtures professional growth, and enables them to explore new frontiers beyond the constraints of conventional methods. By breaking stigma, advancing the field, and advocating for holistic modalities, physicians have the opportunity to play a pivotal role in enhancing the field of mental health and allopathy, offering new hope and potential healing pathways to patients. A new era in Western medicine, where evidence-based methodologies, holistic approaches, and comprehensive care intersect, holds the potential for a transformative landscape on the healthcare horizon.

Posted on August 8, 2023August 8, 2023

PT430 – Psychedelics for Eating Disorders, Davos’ House of Psychedelics, and The Future of the Synthesis Institute

In this episode, Joe interviews Maya Albert: Co-Founder of the Psyched conference, and Director of Operations at Tabula Rasa Ventures and the Synthesis Institute.

She shares her journey of how she became involved in the psychedelic space through her mother, and her personal experience as a patient in a clinical trial on psilocybin for the treatment of anorexia – a much more common and deadly affliction than most people realize. She discusses her involvement with the various psychedelic gatherings surrounding Davos and the World Economic Forum, as well as the work she’s doing with Tabula Rasa and some of their clients seeking to expand insurance coverage to psychedelic-assisted therapy. 

She discusses the Synthesis Institute’s recent struggles that shook up the psychedelic space, what they’re doing to save the company, how Retreat Guru has helped them, and the implications for the wider psychedelic movement. And she talks about much more: the legality and vetting process for training in Oregon and Colorado; truffles in the Netherlands vs. classic psilocybin; the idea of alcohol as poison and ‘Cali sober,’ and how can we all be more collaborative and not sling mud at each other?

Notable Quotes

“The limitations are really when you’ve been in therapy, you’ve seen a nutritionist for five, ten years; you have all the tools there, you know what you’re supposed to do (this can be applied to things like depression or anxiety or any other mental issue), but those neural pathways that have been connecting and forming with those negative thought patterns for decades: for people, they’re not going to undo themselves. It takes more motivation than I have ever had to break my cycles, and I really felt stuck. I don’t think I was going to ever get better than I was at the time without something like psychedelics.”

“It could set the temperature for a lot of other psychedelic organizations and movements to say, ‘This isn’t working and let me show you why. If this goes up in flames, then what else is possible?’ And the space is already greatly under-funded and financiers look at this and they’re like, ‘I’m not touching that with a ten foot pole. This is too early, or this is too risky, or X, Y, and Z.’ So that was really the scary part of the first few weeks of what this meant for the movement at large: if we can’t pull it off, then who can?”

“This whole thing has been like a great big psychedelic trip: use our learning towards being a facilitator, towards facilitating ourselves through this chaos. There has to be chaos within to give birth to a dancing star, I think is what Nietzsche said. We’ll be that dancing star.”

Links

Synthesisinstitute.com

Tabularasa.ventures

Psychedelicspotlight.com: Psychedelic Capitalism Takes a Trip to Davos

Enthea.com

Retreat.guru

Join Kyle and David on August 10th at 222 E 46th St, New York, NY, 7-10pm EST. Click here for tickets!
Posted on August 1, 2023August 1, 2023

PT428 – The Promise of MAPS’ Phase III Data, Psychedelics and Adolescents, and the Need for Honest Drug Education

In this episode, recorded on the eve of MAPS’ Psychedelic Science 2023, Kyle interviews MAPS’ Founder and President, Rick Doblin, Ph.D.

He begins with an overview of the fast-approaching (and largest ever) psychedelics conference, emphasizing its significant growth, many features, and bipartisan opening ceremony, then discusses MAPS’ soon-to-be-released confirmatory Phase III data on MDMA-assisted therapy for PTSD, which should set the stage for legal MDMA and the increasing need for trained psychedelic therapists. 

As the FDA is requiring studies on adolescents, he discusses this sensitive issue and questions why it’s so controversial, since teenage years are often closer to both trauma and a more malleable brain, Indigenous traditions certainly didn’t have age limits, and honest drug education – something that is absolutely necessary to fight the backlash against this quickly growing field – teaches us that it’s not the substance; it’s our relationship to it. Could not having these rites of passage be hurting us?

He also discusses the natural vs. synthetic conflict; breathwork; whether or not cannabis is truly damaging to young minds; Federal rescheduling vs. state rescheduling; why it’s controversial to give therapists MDMA in training; Gul Dolen’s work with reopening critical periods; psychedelics in couples therapy; and much more.

Notable Quotes

“We have been just astonished at the fact that we now have 11,500 people registered for this conference, and we, in our wildest dreams, thought maybe we’d get up to 10,000. But even that was just like a wild dream. The largest psychedelic conference that’s ever happened was our Psychedelic Science in 2017. …Now we’re almost four times as big. It’s a whole different cultural moment, and what I didn’t fully anticipate is how this conference would be like a magnet for the entire community.” 

“I think the proper training of psychedelic therapists is different than the proper training of psychiatrists to administer any kind of pharmacological drugs, because for psychiatry; when they give SSRIs or they give other kinds of medications or they give electroconvulsive therapy or whatever: those are meant to be the treatments. In our case, the treatment is really the human relationship – the therapy – and then the psychedelics make the therapy more effective. And so it makes the most sense for people that are interested in doing psychedelic therapy, for them to have the experience of the psychedelics themselves. As we start to scale, there’s a lot of experienced trauma therapists, but they might not be experienced psychonauts, and it’s hard to describe what a drug does.”

“When you think about these rites of passage, that when you’re an adolescent or early in college, those are the ripe times for people to sort of explore: who are they? Where do they fit into the larger world? I think in many Indigenous cultures, that’s the time of initiation for a lot of people, so I think we have hurt ourselves tremendously. Now, you hear this always about marijuana: ‘kids [have] developing brains and they shouldn’t ever try marijuana.’ And I think the thing is that overuse is a problem. Daily use before you go to school: all that is a problem. It makes it difficult to learn, things like that. But we tend to make sweeping statements like ‘never use.’”

Links

Maps.org

Psychedelicscience.org

Psychedelics Today: PT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials and the Future of Psychedelic Medicine

Numinus.com

Numindhealth.com

Drugpolicy.org

Maps.org: MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation

Posted on July 25, 2023July 25, 2023

PT426 – Making the Impossible Possible: Flow Hacking and Peak Performance Aging

In this episode, Joe interviews one of the world’s leading experts on human performance: New York Times bestselling author and Executive Director of the Flow Research Collective, Steven Kotler.

Kotler’s work explores the neurobiology of peak human performance, flow states, and aging, and the concept of getting our biology to work for us rather than against us in our later years, by using the parts of our brains that expand in our 50s, combined with neuroplasticity, learning by play, and the biggest factor: working toward a very difficult – but not impossible – task. His 30-year exploration of the neurobiology behind people accomplishing ‘impossible’ feats led him to test his theories by teaching himself to park ski at 53 with resounding success, then using his protocol with people up to 70 years old the next season. The story is told in his newest book about challenging tired concepts of aging, Gnar Country. 

He discusses the power of flow states and how much flow actually amplifies productivity, motivation, wisdom, empathy, and more; why dynamic motion is a key activity for greater longevity and why skiing and similar action sports are some of the best examples; why dynamic activity in novel environments is even better; why changing one’s mindset may be the biggest factor toward change; why corporations are looking at flow training and where these concepts could go in the future; and of course, how this all relates to psychedelics. 

Notable Quotes

“If you study flow science, it turns out that flow is really great at helping us go from zero up to Superman. It’s also really great at helping us go from seriously subpar, ‘I’m completely broken and sick’ back to normal. And it turns out this combination is phenomenal in the second half of our lives. And flow sits at the heart of peak performance aging.”

“The only way I can go [from] A to B with this is to take everything I know about flow science and peak performance and see if I can use it to accomplish this so-called impossible task. So that’s what the book is. And yes, I was obviously very successful. I went 0 to 60, as I said, in a single season. It was the fastest I’ve ever actually learned anything.”

“The place you’ve got to begin is mindset. The mind-body connection gets tighter and tighter and tighter over time, and it plays a significant role in aging and peak performance aging. Mindset is the greatest example. …A positive mindset towards aging  – ‘I am thrilled with the second half of my life; my best days are ahead of me’ – translates to an additional eight years of healthy longevity. It’s wild. …You could be morbidly obese and have a shitty mindset towards aging. Change your mindset, you’ll live longer. Don’t lose weight. Change your mindset. It’s more important. In fact, changing your mindset is more important than quitting smoking for healthy longevity.”

Links

Stevenkotler.com

YouTube: Steven Kotler

Flowresearchcollective.com

Gnarcountry.com

When the Impossible Happens: Adventures in Non-Ordinary Realities, by Stanislav Grof

The Structure of Scientific Revolutions, by Thomas S. Kuhn

Getmoreflow.com

The Gnar Country experiment videos

YouTube: Danny Way vs The Great Wall 10 Years Later

Posted on July 21, 2023July 24, 2023

PT425 – The Transformative Potential of Psychedelics, Community, and Live Music

In this episode, David interviews Dr. Gabrielle Lehigh: Co-Founder and Managing Director of Psychedelic Grad, a web-based community serving as an educational and career hub for up-and-coming psychedelic professionals; and the host of the related podcast, “Curious to Serious,” where she speaks with students and professionals about the path they took to land in the psychedelic field. 

Lehigh recently earned her Ph.D. with research on something not many are looking at: the stories behind powerful and transformative psychedelic experiences specifically at music events, based on 38 interviews and over 500 surveys mostly collected at day-long festivals in the southern United States. While the goal was largely data collection in support of the clear potential for therapeutic benefit in using psychedelics in recreational settings (as many of us who have experienced this can attest), she was surprised to learn how many people still blindly trust dealers; how much festival security can affect safety; how the community often makes more of a difference than the music itself; and how many parallels exist between colder clinical models of psychedelic-assisted therapy and the completely open festival experience. 

She discusses how she found her way from environmental justice to psychedelics; what people are most looking for on Psychedelic Grad; why she chose to use the word “transformative” in her research; what music she has had her best experiences with; why psychonauts shouldn’t forget about Pink Floyd; and much more.

Notable Quotes

“I went to my advisor at the time and I said, ‘Listen, I want to change the direction that I’ve been going in.’ I’m like, ‘I either want to study the anthropology of space colonization,’ (which is so out there) ‘or I want to study psychedelics.’ And my advisor was like, ‘Neither one of those is anywhere near what you were studying before. What happened?’”

“I can be somewhat frustrated sometimes when, from the clinical setting, there’s this idea that recreational use has no benefit for people, because I’ve seen it from other people’s experiences, [and] there have been experiences that I’ve had in those types of recreational settings that have been incredibly beneficial for me. Even when I started taking psychedelics, even though I was taking them at home; it wasn’t clinical, it wasn’t medical, it wasn’t necessarily therapeutic as defined by ‘therapeutic,’ so it was still considered recreational. So I was just really frustrated in seeing repeated notions that recreational isn’t necessarily beneficial. And so I set out to be like: well, if it’s not beneficial, then maybe we should go check it out and see what’s really going on.”

“When we think about the clinical setting, when we look at the MAPS protocol and everything, music is a part of it. But in the interviews, people talked about the value of live music. There’s something special and something unique about music being created in the moment, and you, as a spectator, are part of the creation of that music, and there’s something really special going on there. …It’s the music, and it’s not just the music as the music, it’s this live production of the music. There’s some type of magic in it.”

Links

Psychedelicgrad.com

Curious to Serious podcast

Curious to Serious podcast: David Drapkin – Working In The Psychedelic Space

“Transformative Psychedelic Experiences at Music Events: Using Subjective Experience to Explore Chemosocial Assemblages of Culture,” by Gabrielle R. Lehigh (her full dissertation)

Prohibited Practice: Drug Use, Harm Reduction and Benefit Enhancement in Toronto Rave Culture, by Hilary Agro

Sciencedirect.com: The pleasure in context,” by Cameron Duff

Israeli Harm Reduction – A Real World Trip From Raves to Parliament (A Psychedelics Today webinar)

Bassdrive.com

YouTube: Grateful Dead – Terrapin Station (Anaheim, CA 7/26/87)

Spotify: Pink Floyd – The Dark Side of the Moon

Spotify: “Top 40 Hits from Gabby’s Trips” (the playlist she discussed at the end of the episode)

Posted on July 7, 2023July 24, 2023

PT421 – The Impact of the Therapeutic Alliance on the Psychedelic Experience

In this episode, David interviews Dr. Roberta Murphy: training medical psychotherapist and member of the Imperial Centre for Psychedelic Research.

This is a rare impromptu podcast, recorded about a half hour after David heard Murphy speaking on a panel at UK’s Breaking Convention conference. He asked her if she wanted to be on the podcast sometime, and before they knew it, they were recording. Fastest turnaround ever?

She discusses her past research and what she’s doing at Imperial College; her work on a psilocybin for depression trial; her hopes for psychedelics treating people with Parkinson’s; and her recent co-written paper on the ARC Framework (Access, Reciprocity and Conduct), where she will be focusing strongly on the Conduct aspect through her work at Imperial. 

And she talks about her other paper exploring the impact of one of the more important aspects of therapy: the therapeutic alliance on the psychedelic experience. How does the treatment dynamic between the therapist and the client impact the outcome (and course) of the therapy, and what determines whether it’s neutral, negative, positive, or very positive?

Notable Quotes

“It makes sense in a way that you might need to kind of work through those mistrust feelings before you get into a deeper layer, and then in the next session they were able to (I think because they felt a bit safer with us) let go and have a bit more of a typical psychedelic experience where they visualized things and saw things. …I think that that can often then be mistaken as resistance or like nothing’s happening. But there’s always something happening, it’s just sometimes it’s a little bit more nuanced or a little bit harder to pick up and work with. But there’s always something happening. You just might have to zoom in a bit to see it.”

“There’s a difference between a challenging experience that occurs, is processed, and worked through vs. a challenging experience where people kind of never really work with it, it doesn’t get processed, and they get quite stuck in it. …I do think that if you have a good container of a therapeutic relationship, it can help you to work through and process, and I think if you don’t have that, it’s more likely that you’ll end up with something a bit stuck, because I think in order to process, you often need to go in and go deep. And if you don’t feel safe to do that, you’re just going to kind of float on the edge, in a way, and never quite get through.”

Links

Researchgate.net: Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Researchgate.net: ARC: a framework for access, reciprocity and conduct in psychedelic therapies

Posted on June 27, 2023June 27, 2023

PT419 – Ketamine-Assisted Therapy for Severe Alcohol Use Disorder

In this episode, David interviews Professor Celia Morgan, Ph.D., who holds the Chair of Psychopharmacology and co-leads the Transdisciplinary Psychedelics Group at The University of Exeter.

This was recorded on the dawn of UK’s Breaking Convention conference, where Morgan was speaking about the therapeutic potential of ketamine as well as the danger of people developing a dependence on it. She touches on that topic, but largely discusses her current Phase III Trial for ketamine-assisted therapy for the treatment of severe alcohol use disorder (also called the KARE model (Ketamine for reduction of Alcohol Relapse)), a collaboration with Awakn Life Sciences.

She discusses her other research: studies on mindfulness intervention before and after ketamine, epigenetic changes after ayahuasca use, the antidepressant qualities of ayahuasca, and CBD for cannabis dependence. And she talks about the necessary balance for making treatments amazing but affordable; how connecting with nature during integration is key; how the drug is just a tool, yet we focus on it too much; and how we need studies on how different therapies work with different substances.

Notable Quotes

“People always focus on the drugs, but it’s more about the people, and as you say, their relationship – what you’re getting from that experience. The drugs themselves are just tools. You can hit someone over the head with a spade, but you can dig an amazing garden. I see the drugs as the spade, basically, but obviously a really unusual spade.”

“Taking a step back from your thoughts and not being over-engaged with everything you’re doing; the ketamine really helps to facilitate that, because they can see how that works. Mindfulness can be really tricky. Mindfulness practice is hard work. So I see this as a big step that makes it work better in that first bit, especially when people are struggling. …Ketamine, to my mind, gives this kind of boost and insight that can help engage them with the therapy going forward.” 

Links

A Vital Journey: Transpersonal Breathwork Retreat in PA, July 28

Check out the Lumenate app, and download it through the App store here!

University of Exeter department of Psychology: Professor Celia Morgan

Ketamine for reduction of Alcoholic Relapse (KARE)

Awaknlifesciences.com: Awakn Life Sciences Signs Collaboration Agreement With University of Exeter for Upcoming Phase III Trial

Breakingconvention.co.uk

Nice.org.uk: Nasal spray medicine for treatment-resistant depression not recommended by NICE

The NHS Talking Therapies for anxiety and depression program (formerly known as Improving Access to Psychological Therapies (IAPT))

Nushama.com

Awaknlifesciences.com: Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Frontiersin.org: Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Journals.sagepub.com: Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years

Thelancet.com: Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial

Posted on June 23, 2023June 27, 2023

PT418 – Psychedelic Morning Show #2 with Joe Moore and Anne Philippi

In the second episode of our special, two-part series, the Psychedelic Morning Show, Joe Moore and Anne Philippi are live once again bright and early from Psychedelic Science 2023 in Denver. Listen to this podcast as they interview four guests working on the front lines of psychedelic research, law, and the treatment of chronic pain.

Guests for this episode include: 

  • Tommaso Barba – PhD candidate at Centre for Psychedelic Research, Imperial College London
  • Allison Hoots – Attorney at Hoots Law Practice and advocate; President of Sacred Plant Alliance
  • Bob Wold – Founder & President, Clusterbusters
  • Court Wing – Founder, REMAP Therapeutics

Links

Imperial College London Centre for Psychedelic Research

Sacred Plant Alliance

Hoots Law Practice

Clusterbusters

PT404 – Clusterbusters: The Horrors of Cluster Headaches and the Miracle of Psilocybin

Court Wing – Pain and Its Relationship to the Mind

REMAP Therapeutics

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain, by Court Wing

Why Did Psychedelics Relieve My Chronic Pain? by Court Wing

Posted on June 22, 2023June 27, 2023

PT417 – Psychedelic Morning Show #1 with Joe Moore and Anne Philippi

Psychedelics Today is reporting live this week from the industry event of the year, Psychedelic Science 2023 in Denver. Listen in to this podcast as our co-founder, Joe Moore, and New Health Club founder Anne Philippi hit the conference floor bright and early in the first episode of a special two-part series, the Psychedelic Morning Show.

In this limited series, Joe and Anne chat in real-time with guests working in all corners of the psychedelic ecosystem, from advocacy, law and finance, to research and therapy. 

Guests for this episode include: 

  • Dr. Julie Holland – Psychiatrist, psychedelic researcher, author and medical advisor for MAPS
  • Daniel Goldberg – Co-Founder and Principal at Bridge Investments & Palo Santo
  • Hadas Alterman – Director of Government Affairs | American Psychedelic Practitioners Association
  • Melissa Lavasani – Founder and Chief Executive Officer at Psychedelic Medicine Coalition, Founder and President of Psychedelic Medicine PAC
  • Tracey Tee – Founder of Moms on Mushrooms

Links

DrHolland.com

MAPS

Working Weekends at a Psych ER – Interview with Julie Holland on NPR

Bridge Investments

Palo Santo

American Psychedelic Practitioners Association

PT249 – Hadas Alterman, Serena Wu, and Adriana Kertzer of Plant Medicine Law Group

Psychedelic Medicine Coalition

Psychedelic Medicine PAC

PT338 – Melissa Lavasani – The Power of Storytelling, The Preservation of Peyote, and “How to Change Your Mind”

PT405 – The Psychedelic Medicine PAC: The Push for Federal Funding and Politicians Who Will Fight for Us

Moms on Mushrooms

PT396 – Moms on Mushrooms: Motherhood and Psychedelics Inside a Broken Culture

Posts navigation

Page 1 Page 2 … Page 16 Next page

Keeping Tabs

A microdose of all things psychedelic news, all in one place. Get bi-weekly updates, education, and events straight to your inbox.

We won’t share your information. Unsubscribe at any time.

pt_logo_white (1)

Psychedelics Today is the planetary leader in psychedelic media, storytelling, and education.

Menu
  • Podcasts
  • Articles
  • Events
  • About
  • Press
  • Become a Navigator
  • Contact
Subscribe to our newsletter
Visit Our Other Sites
  • Education Center
  • Vital
  • Shop
  • Navigators
Subscribe to our Podcast
© Psychedelics Today. All rights reserved. Privacy | Terms & Conditions